The p85 Adapter Subunit
Class IA PI3Ks are tightly associated with a 85 kDa regulatory subunit called p85.[1] P85 contains a Src homology 3 (SH3) domain, a breakpoint-cluster region homology (BH) domain between two proline-rich regions, and two C-terminal SH2 domains separated by an inter-SH2 (iSH2) region, which tightly binds p85 to the catalytic subunit.[2] Since PI3K has multiple protein-interaction domains, p85 is able to interact with several signaling molecules simultaneously, allowing for significant fine tuning of PI3K activity. [1]
Src Homology 3 (SH3) Domain
The SH3 domain of PI3K has homologues found in many intracellular signaling proteins. [3] It mediates protein-protein interactions by binding to proline-rich motifs in target proteins forming multimeric signaling complexes. [4] Of note, the SH3 domain interacts with Src (Src homology 2/α-collagen-related), CDC42GAP (Cdc42 GTPase-activating protein) and the proto-oncogene product Cbl. SH3 binds to proline rich ligands via a network of hydrophobic and hydrogen bond interactions, particularly with the conserved residues Trp 55, Pro 70, and Tyr 73 (3i5r).[3]
Proline-Rich Regions
The proline rich regions which flank the BH domain are ideal ligands for various SH3 containing non-receptor protein tyrosine kinases like Src, Lyn & Fyn, often with the product of the proteo-oncogene product Cbl as a docking site. [5]
Src Homology 2 (SH2) Domains
PI3K has two SH2 domains, an N-terminal (nSH2) domain and a C-terminal (CSH2) domain. [6] Both domains recognize similar consensus phosphorylated tyrosine motifs with the pattern: pY-V-X-M in activated receptors and adaptor proteins like PDGF, erbB3, c-Kit and CSF-1 receptors. [7] It is upon the interaction of receptor and SH2 domain that the heterodimeric PI3K complex is activated. [8] The docking site for receptor in NSH2 is defined by the conserved residues Arg 340, Arg 358, and Thr 371 (2iui), all of which coordinate the phosphorylated tyrosoine phosphate group.[9] nSH2 was found to interact with the catalytic subunit directly, forming a broad-based scaffold for p110α and coordinates communication between the interacting domains. (Discussed Below). [10]
BH Domain
The BH domain specifically interacts with the Rho family proteins, Cdc42 and Rac1. Although no crystal structure of the BH domain has been solved to date, mutagenesis experiments have verified that the conserved residues Arg 151, Lys 187 and Pro 270 play important roles in the interaction with Rac1 and Cdc42. [1]
Inter-SH2 (iSH2) Region
The iSH2, two long coiled alpha helices (2v1y), is flanked by the two SH2 domains. The primary purpose of the iSH2 is to tightly bind the adaptor-binding domain (ABD) on the catalytic p110 subunit (3hhm), effectively holding the PI3K heterodimer together. In fact, disruption of this interaction via antibodies prevents the formation of the PI3K heterodimer completely. [1] It is further believed that binding of phosphopetide by the SH2 domains causes conformational strains which is propagated to the catalytic subunit directly and via the iSH2[1]
Regulation of Class IA PI3K via p85 Phosphorylation
All PI3K catalytic subunits possess intrinsic protein serine kinase activity. PI3K regulatory subunits can be phophorylated by the catalytic subunit (p110) at specific sites. For example, phophorylation of Ser 608, a residue located in an area of the iSH2 domain that is critical for PIP2 presentation to the catalytic subunit, results in a dramatic reduction in PI3K lipid kinase activity.[11] Additionally, tyrosines 580 and 607 can be phosphorylated upon stimulation with insulin and growth factor along with Tyr 508 upon PDGF receptor mediation. [1] Phosphorylation of Tyr 688 in the CSH2 domain by Abl and Lck results in reduced affinity for phosphopeptides and subsequent activation of the catalytic domain. [12]
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta. 1998 Dec 8;1436(1-2):127-50. PMID:9838078
- ↑ Otsu M, Hiles I, Gout I, Fry MJ, Ruiz-Larrea F, Panayotou G, Thompson A, Dhand R, Hsuan J, Totty N, et al.. Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell. 1991 Apr 5;65(1):91-104. PMID:1707345
- ↑ 3.0 3.1 Batra-Safferling R, Granzin J, Modder S, Hoffmann S, Willbold D. Structural studies of the phosphatidylinositol 3-kinase (PI3K) SH3 domain in complex with a peptide ligand: role of the anchor residue in ligand binding. Biol Chem. 2010 Jan;391(1):33-42. PMID:19919182 doi:10.1515/BC.2010.003
- ↑ Koch CA, Anderson D, Moran MF, Ellis C, Pawson T. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science. 1991 May 3;252(5006):668-74. PMID:1708916
- ↑ Dombrosky-Ferlan PM, Corey SJ. Yeast two-hybrid in vivo association of the Src kinase Lyn with the proto-oncogene product Cbl but not with the p85 subunit of PI 3-kinase. Oncogene. 1997 May 1;14(17):2019-24. PMID:9160881 doi:10.1038/sj.onc.1201031
- ↑ Cite error: Invalid
<ref> tag; no text was provided for refs named Flip
- ↑ Weber T, Schaffhausen B, Liu Y, Gunther UL. NMR structure of the N-SH2 of the p85 subunit of phosphoinositide 3-kinase complexed to a doubly phosphorylated peptide reveals a second phosphotyrosine binding site. Biochemistry. 2000 Dec 26;39(51):15860-9. PMID:11123912
- ↑ Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 2007 Jul 13;317(5835):239-42. PMID:17626883 doi:317/5835/239
- ↑ Nolte RT, Eck MJ, Schlessinger J, Shoelson SE, Harrison SC. Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes. Nat Struct Biol. 1996 Apr;3(4):364-74. PMID:8599763
- ↑ Cite error: Invalid
<ref> tag; no text was provided for refs named Amzel
- ↑ Dhand R, Hiles I, Panayotou G, Roche S, Fry MJ, Gout I, Totty NF, Truong O, Vicendo P, Yonezawa K, et al.. PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J. 1994 Feb 1;13(3):522-33. PMID:8313897
- ↑ von Willebrand M, Williams S, Saxena M, Gilman J, Tailor P, Jascur T, Amarante-Mendes GP, Green DR, Mustelin T. Modification of phosphatidylinositol 3-kinase SH2 domain binding properties by Abl- or Lck-mediated tyrosine phosphorylation at Tyr-688. J Biol Chem. 1998 Feb 13;273(7):3994-4000. PMID:9461588